In August 2015, U.S. Renal Care, Inc. announced a $640 million acquisition of DSI Renal. Both companies provide life-sustaining hemodialysis and peritoneal dialysis services for end-stage renal disease. A Compass Lexecon team including Jon Orszag, Eugene Orlov, Otto Hansen and Ben Xiao was retained by Marc Williamson, Amanda Reeves, and Kory Wilmot from Latham & Watkins LLP, outside counsel for U.S. Renal Care, to analyze the competitive effects of the proposed merger. We helped counsel present empirical evidence to the Federal Trade Commission (FTC) of the limited scope of potential anticompetitive harm from the merger. In late December 2015, the companies reached a favorable settlement with the FTC, requiring minimal divestitures in only one local market. The combined company will serve approximately 23,000 patients across 33 states and the Territory of Guam. The Compass Lexecon team also worked with Gorav Jindal and Konstantin Medvedovsky from Dechert LLP.